Lilly Asia Ventures — Full Portfolio
92 tracked investments · listed companies and verified rows first
PartnerHongbo Lu· solo GP
Co-investorsLAVNew Enterprise Associates (NEA)Nextech InvestNSG Ventures
Legend Biotech is a biotechnology company.
BiotechSomerset, US
Yuan Xu, Ph.D.(Executive Officer, Director)Ying Huang, Ph.D.(Executive Officer)Fangliang Zhang, Ph.D.(Director)Ye Wang, M.S.(Director)
PartnerHongbo Lu· solo GP
Co-investorsLAV
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)
PartnerHongbo Lu· solo GP
Co-investorsBay City CapitalCanaan PartnersLAVPfizer Venture InvestmentsQuan CapitalSofinnova Ventures+2 more
ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.
BiotechHealthtechMedical Devices
Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)Ryan Fisk(Chief Financial Officer & Chief Business Officer)Robert A. MacLeod(Chief Scientific Officer)inChristopher Claeboe(Senior Vice President of Operations)
Co-investorsOrbiMedBain Capital Life SciencesSR One Capital ManagementT. Rowe PriceTCG CrossoverVivo Capital
Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.
BiotechHealthtechLongevity
Geoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)
Co-investorsMPM BioImpactDCVC BioVersant VenturesDCVC (Data Collective)
Fortis Therapeutics develops therapeutic treatments based on technology licensed from UCSF, with a focus on oncology and other disease areas.
BiotechHealthtechMedical DevicesSan Diego, US
Marc Nasoff(Chief Scientific Officer)
BoardJay B. Lichter(Ph.D.)
Co-investorsVivo CapitalOsage University PartnersAvalon BioVenturesOUP (Osage University Partners)
Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.
BiotechHealthtechMedical DevicesSuzhou, CN
William Wei Cao
PartnerHongbo Lu· solo GP
Co-investorsLAVOrbiMedExome Asset ManagementJanus Henderson InvestorsPivotal Life SciencesRA Capital+2 more
Insilico Medicine uses artificial intelligence to discover and develop new drugs, operating an AI-driven platform for pharmaceutical research and development.
AI & Machine LearningBiotechDigital HealthHealthtechHong Kong
Alex Zavoronkov(Director)Alex Zhavoronkov(Founder & CEO)Alex Aliper(President)Feng Ren(Chief Scientific Officer, Executive Director & Co-CEO)
BoardNisa Leung(Director)Lennart Lee(Director)
PartnerHongbo Lu· solo GP
Co-investorsOrbiMedQiming Venture PartnersWarburg PincusBaidu VenturesEight Roads VenturesLake Bleu Capital+9 more
QuantX Bio applies a proprietary computational platform to accelerate the discovery and optimization of drug candidates.
AI & Machine LearningBiotechDeep Tech
Co-investorsOrbiMedSanofi VenturesCreacion Ventures
San Diego, US
Board seatHongbo Lu· per SEC Form D · $5M raise · filed Aug 2020
Co-investorsAscenta CapitalLAVSilverArc PrivateTCG Crossover
BiotechHealthtechMedical DevicesWaltham, US
David F. Muller(Executive Officer, Director)inBrian J. Roberts(Executive Officer)inRhonda J. Bracey(Executive Officer)in
BoardJason Hong(Director)Jeff Dykan(Director)inAnthony Natale(Director)in
Board seatHongbo Lu· per SEC Form D
Co-investorsAPERTURE Venture PartnersLAVSCP Vitalife PartnersThird Point VenturesHealthQuest CapitalOrbiMed
BiotechSan Diego, US
JINGRONG JEAN CUI(Executive Officer, Director)Jingrong Jean Cui(Executive Officer, Director)YISHAN LI(Executive Officer, Director)Li Peter Yishan(Executive Officer, Director)
BoardGEORGE LEE(Director)CARL GORDON(Director)
Board seatHongbo Lu· per SEC Form D · $100M raise · filed Jan 2024
Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms.
BiotechHealthtechMedical DevicesSan Francisco, US
Sevgi Gurkan, MD(Founder, Chief Executive Officer, and Member of the Board of Directors)
BoardChristy Shaffer(Director)Chau Khuong(Director)inSevgi Gurkan(Executive Officer, Director, Promoter)in
Board seatHongbo Lu· per SEC Form D
Co-investorsOrbiMedAccess BiotechnologyCatalio Capital Management, LPHatteras Venture PartnersLAVHatteras
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)inHualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)inSimon Xi(Co-founder and CEO)inJackie Walling(CMO)Debasish Roychowdhury(Director)
Board seatHongbo Lu· per SEC Form D · $38M raise · filed Mar 2021
Co-investorsDelos CapitalVivo CapitalAMR Action FundBoehringer Ingelheim Venture FundKorea Investment PartnersMatrix Partners China
HealthtechCampbell, US
Amr Salahieh(Executive Officer, Director)David Voris(Executive Officer)
BoardMariam Maghribi(Director)Gautam Kainth(Director)Bihua Chen(Director)
Co-investorsAmed VenturesQatar Investment AuthorityThe Capital PartnershipUnorthodox Ventures
An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.
BiotechDigital HealthHealthtechMedical DevicesShanghai, CN
PartnerHongbo Lu· solo GP
Co-investorsLAVQuan Capital3E Bioventures CapitalSherpa Healthcare Partners
Allist (艾力斯医药) is a biopharmaceutical company that develops innovative drugs, with a product pipeline focused on treatments for non-small cell lung cancer (NSCLC) such as its EGFR-targeted therapy marketed as Furmonertinib (艾弗沙®).
BiotechHealthtech
PartnerHongbo Lu· solo GP
Ansun develops novel therapeutic treatments targeting viral diseases, particularly respiratory infections, through its proprietary sialic acid biology platform.
BiotechDigital HealthMedical DevicesSan Diego, US
RONALD MOSS(Executive Officer)inMARK ATTEBURY(Executive Officer)inMIKAEL HAVLUCIYAN(Executive Officer)
BoardALLEN CHAO(Director)MICHAEL CHANG(Director)NANCY CHANG(Director)
PartnerHongbo Lu· solo GP
Co-investorsLAV
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
PartnerHongbo Lu· solo GP
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHongShan Capital GroupLAVOrbiMed+2 more
Burning Rock Dx is a diagnostics company that applies next-generation sequencing (NGS) technology to precision oncology, offering NGS-based assays for tissue and blood samples along with an in-house database.
BiotechDigital HealthMedical Devices
PartnerHongbo Lu· solo GP
Co-investorsLAV
Xian-ping LU(Founder)in
PartnerHongbo Lu· solo GP
Co-investorsLAVLYZZ CapitalVertex Ventures China
Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.
BiotechFemTechHealthtechConcord, US
Mike Young(Founder)inT Scott Johnson(Founder)inPaul Antinori(Executive Officer)Allison August(Executive Officer)inMichael Young(Executive Officer)Thomas Scott Johnson(Executive Officer, Director)
Co-investorsAtlas VentureGV (Google Ventures)Broadview VenturesF-Prime CapitalNew Enterprise Associates (NEA)
Connect Biopharm develops next-generation therapeutics for inflammatory diseases.
Biotech
PartnerHongbo Lu· solo GP
Co-investorsLAVQiming Venture Partners
CorrectSequence Therapeutics develops base-editing gene therapies using its proprietary transformer Base Editor (tBE) platform to treat genetic diseases, rare diseases, and common conditions including inherited disorders, metabolic diseases, cardiovascular diseases, and cancers.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesShanghai, CN
陈佳(Founding Professor / Chief Scientific Advisor)牟晓盾(Chief Executive Officer)
PartnerHongbo Lu· solo GP
Co-investorsLAV
Lang Lai Technology (朗来科技) is a clinical-stage drug discovery company that runs an end-to-end new-drug R&D process spanning proof of concept, candidate compound screening, preclinical druggability development, and clinical research, pursuing both pipeline development and platform building.
BiotechHealthtechWuhan, CN
Co-investorsOrbiMedVivo Capital
Crown Bioscience is a contract research organization based in California providing discovery, preclinical, and translational platforms and services for oncology and immuno-oncology drug development.
BiotechHealthtechMedical DevicesCalifornia, US
PartnerHongbo Lu· solo GP
Co-investorsAcorn Pacific VenturesGRC SinogreenLAVQiming Venture Partners
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
BiotechDigital Health
PartnerHongbo Lu· solo GP
Co-investorsLAVMPM BioImpactSchooner CapitalTaiho Ventures, LLC
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform.
BiotechDeep TechHealthtech
PartnerHongbo Lu· solo GP
Co-investorsLAVWI Harper Group
Skyline Therapeutics develops gene therapy vector technology and supports clinical development for therapeutic applications using genetic science approaches.
BiotechDeep TechHealthtech
PartnerHongbo Lu· solo GP
Co-investorsF-Prime CapitalLAV
Geneseeq develops next-generation sequencing (NGS) based genetic tests and in-vitro diagnostic products for cancer patients, using gene profiling to guide targeted drug selection, indicate drug resistance mechanisms, and monitor post-surgical recurrence.
AI & Machine LearningBiotechDigital HealthNanjing, CN
PartnerHongbo Lu· solo GP
Co-investorsLAV
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.
BiotechDeep TechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
PartnerHongbo Lu· solo GP
Co-investorsBay City CapitalGV (Google Ventures)LAV
Huamai Taike develops and manufactures medical devices including vascular stents, catheters, guidewires, and hemostatic devices for interventional vascular and neurovascular procedures.
HardwareHealthtechMedical DevicesBeijing, CN
PartnerHongbo Lu· solo GP
Co-investorsLAV
Inhibrx develops protein therapeutics, using target biology and protein engineering to create therapeutic candidates in clinical trials for conditions including sarcoma and head and neck cancer.
BiotechLa Jolla, US
Mark Lappe(Executive Officer, Director)inBrendan Eckelman(Director)inDoug Forsyth(Director)Jon Faiz Kayyem(Director)Margery Fischbein(Director)
BoardJudith Li(Director)
PartnerHongbo Lu· solo GP
Co-investorsLAVRA CapitalOxford Finance LLC
PartnerHongbo Lu· solo GP
Co-investorsF-Prime CapitalLAVLegend Capital
InventisBio is a China-based drug discovery company developing patent-protected small-molecule targeted therapies for oncology and metabolic diseases.
BiotechHealthtechShanghai, CN
Xing Dai(Founder)inYaolin Wang(Chairman & General Manager (Co-founder))
PartnerHongbo Lu· solo GP
Co-investorsLAVOrbiMedQiming Venture Partners
Jacobio is a biopharmaceutical company developing novel oncology therapeutics, focusing on next-generation antibody-conjugated drugs including ATDCs, ISACs, and AOCs to treat cancer patients.
BiotechDeep TechHealthtechMedical DevicesBeijing, CN
Wang Yinxiang(Chairman and Co-Chief Executive Officer)Wang Yi(Co-Chief Executive Officer, Chief Medical Officer)
PartnerHongbo Lu· solo GP
Co-investorsLAVQiming Venture Partners
A biopharmaceutical company developing targeted cancer drugs and related therapies.
BiotechHealthtechMedical DevicesShanghai, CN
Co-investorsDecheng CapitalQiming Venture Partners
Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.
BiotechMedical Devices
Co-investorsForesite CapitalNextech InvestAlexandriaLongwood Fund
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)JAMES GILBERT(Director)
BoardALAN L. CRANE(Director)
PartnerHongbo Lu· solo GP
Co-investorsAlpha Wave GlobalARCH Venture PartnersFlagship PioneeringLAVBaillie GiffordPolaris Partners
Lupeng Pharmaceutical develops next-generation small-molecule targeted drugs for malignant tumors and autoimmune diseases, focusing on hematologic cancer targets such as BTK, Bcl-2, and Bcl-xL, with multi-center clinical development and commercialization in international and Chinese markets.
BiotechHealthtech
周正清(首席财务官 (CFO))Stephen Anthony(首席医学官 (Chief Medical Officer))
PartnerHongbo Lu· solo GP
Lynk Pharma develops pharmaceutical products for rheumatoid arthritis and ankylosing spondylitis, with selective licensing arrangements for regional commercialization.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesHangzhou, CN
Zhao-Kui (ZK) Wan(Founder, Chairman of Board & CEO)Michael Vazquez(Co-founder & Executive Vice President)Jun Wang(Co-founder & CSO)Yan Chen(Co-founder & COO)
PartnerHongbo Lu· solo GP
Co-investorsDecheng CapitalLAV
PartnerHongbo Lu· solo GP
Co-investorsB Capital GroupB4 CapitalF-Prime CapitalLAVMarathon Venture Partners
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
PartnerHongbo Lu· solo GP
Co-investorsage1EcoR1 CapitalLAVNew Enterprise Associates (NEA)Vivo CapitalARCH Venture Partners+2 more
MicroTech Medical provides medical information services in China, with operational headquarters in Hangzhou and a principal place of business in Hong Kong.
Digital HealthHardwareMedical DevicesHangzhou, CN
PartnerHongbo Lu· solo GP
Co-investorsLAVLYZZ CapitalQiming Venture Partners
PartnerHongbo Lu· solo GP
Co-investorsAcorn Pacific VenturesLAVLegend Capital
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.
BiotechHealthtechWilmington, CN
Yan Lou(Founder)Zhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)
BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)
PartnerHongbo Lu· solo GP
Co-investorsEcoR1 CapitalLAVRA CapitalSamsara BioCapitalThe Innovation SpaceLogos
Nucleix is a healthcare company developing diagnostic technology based on DNA/nucleic acid analysis for cancer detection.
BiotechDigital HealthHealthtechMedical Devices
Eli Frydman(President EMEA)
Co-investorsGefen CapitalOrbiMedRA CapitalBlackRockLYFE CapitalSands Capital Ventures
BiotechCampbell, US
Amr Salahieh(Executive Officer, Director)Casey Gordon(Director)Mariam Maghribi(Executive Officer)
PartnerHongbo Lu· solo GP
Co-investorsLAV
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)Sylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)Toni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
Co-investorsIllumina Ventures5AM VenturesOUP (Osage University Partners)Osage University Partners
PartnerHongbo Lu· solo GP
Co-investorsB Capital GroupB4 CapitalLAVLYFE CapitalNextech InvestRA Capital
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.
BiotechDeep TechHardwareHealthtechCambridge, US
Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)
BoardYuh-Geng Tsay(Director)Victor Tong(Director)Thomas Grogan(Director)
PartnerHongbo Lu· solo GP
Co-investorsLAVLilly VenturesVivo Capital
Regor is a drug discovery company that uses a computational platform (rCARD) to identify and optimize preclinical small-molecule candidates in metabolism, oncology, and immunology, which it licenses to pharmaceutical companies for clinical development.
AI & Machine LearningBiotechDeep TechShanghai, CN
Xiayang Qiu(Founder)in
PartnerHongbo Lu· solo GP
Co-investorsLAVVertex Ventures
RemeGen is a biopharmaceutical company that develops and commercializes novel antibody and fusion protein therapeutics, including telitacicept (a BLyS/APRIL dual-target fusion protein) and disitamab vedotin, for conditions such as autoimmune diseases and cancers.
BiotechHealthtechYantai, CN
王威东(Co-founder)房健民(Co-founder)
PartnerHongbo Lu· solo GP
Co-investorsLAV
Rona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH.
BiotechLongevityShanghai, CN
Jinyu Huang(Chief Executive Officer, Founder)Stella Shi(Founder & Chief Executive Officer, Chair of the Board)Stella (Yibin) Shi(Founder)
PartnerHongbo Lu· solo GP
Co-investorsLAV
Ronovo Surgical develops the Carina surgical robotics platform, including a vision system and instruments, for use by surgeons and hospitals.
HealthtechMedical DevicesRoboticsShanghai, CN
John Ma(Founder)Ying Mao(Founder)in
Co-investorsGranite AsiaINCE CapitalVivo CapitalJJDC
Singlera Genomics develops DNA methylation-based molecular diagnostics for cancer, covering early detection, diagnosis, and recurrence monitoring across multiple cancer types including colorectal, liver, gastric, esophageal, and pancreatic cancers.
BiotechHealthtechMedical DevicesShanghai, CN
PartnerHongbo Lu· solo GP
Singleron Biotechnologies develops single-cell and single-nucleus sequencing kits and solutions for transcriptome analysis of biological samples.
BiotechMedical DevicesCologne, DE
PartnerHongbo Lu· solo GP
Co-investorsARCH Venture PartnersLAVMSA Capital
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Executive Officer, Director, Promoter)in
BoardFan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)
PartnerHongbo Lu· solo GP
Co-investors8VCARCH Venture PartnersFrazier Life SciencesJDRF T1D FundLAVLifeforce Capital+1 more
Sperogenix (曙方医药) is a biopharmaceutical company focused on developing and commercializing drugs for genetic rare diseases in China, covering areas such as neuromuscular disorders, neurodevelopmental disorders, inherited metabolic diseases, and blood disorders.
BiotechHealthtech
PartnerHongbo Lu· solo GP
Co-investorsLAV
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.
BiotechHealthtechBrisbane, US
Stephen Brady(Director)Matthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)Thomas Woiwode(Director)Geoffrey Nichol(Director)Thomas W. Dubensky(Executive Officer, Director)
PartnerHongbo Lu· solo GP
Co-investorsF-Prime CapitalLAVNew Enterprise Associates (NEA)Quan CapitalRoche Venture Fund
Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program.
BiotechHealthtechFoster City, US
Mark Vignola, Ph.D.(Executive Officer)Bryan Yoon(Executive Officer)inSenthil Sundaram(Director, Executive Officer)inWeidong Zhong, Ph.D.(Executive Officer, Director)Jill Quigley(Director)David Fellows(Director)
PartnerHongbo Lu· solo GP
Co-investorsDecheng CapitalLAVVivo Capital
BiotechPhiladelphia, US
Anne Chew(Director and President)
BoardKevin Mahoney(Director)
PartnerHongbo Lu· solo GP
Co-investorsAndreessen HorowitzKleiner PerkinsLAVMilitia Hill VenturesGilead Sciences
PartnerHongbo Lu· solo GP
Co-investorsForesite CapitalLAVNextech InvestSv Tech Ventures, Inc.
PartnerHongbo Lu· solo GP
Co-investorsLAVPfizer Venture Investments
Innovative biopharma company focused on cancer and immune disease therapies (SHSE: 688192).
PartnerHongbo Lu· solo GP
Co-investorsHongShan Capital GroupLAV
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.